Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster…
Tag: Akero
Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (NASDAQ:AKRO)
This article was written by Follow Avisol Capital Partners is made up of a team of…
Akero Therapeutics CEO sells shares worth $78,001
Akero Therapeutics CEO sells shares worth $78,001#Akero #Therapeutics #CEO #sells #shares #worth
Akero Therapeutics' chief scientific officer sells shares worth $23,158
Akero Therapeutics' chief scientific officer sells shares worth $23,158#Akero #Therapeutics039 #chief #scientific #officer #sells #shares #worth
Akero therapeutics COO Jonathan Young sells $2.24 million in stock
Akero therapeutics COO Jonathan Young sells $2.24 million in stock#Akero #therapeutics #COO #Jonathan #Young #sells #million…
Akero Therapeutics' chief scientific officer sells $1.74 million in stock
Akero Therapeutics' chief scientific officer sells $1.74 million in stock#Akero #Therapeutics039 #chief #scientific #officer #sells #million…
Akero: Reversal Of Cirrhosis With EFX Is A “First” In F4 MASH Patients (NASDAQ:AKRO)
This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector…
The Stock That’s Making Waves: Akero Therapeutics (AKRO)
Today was a day of surprises in the market, and one stock that caught my attention…
Akero Therapeutics: Where This Potential MASH Play Stands Currently
Akero Therapeutics: Where This Potential MASH Play Stands Currently #Akero #Therapeutics #Potential #MASH #Play #Stands
Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm By Investing.com
New York, New York–(Newsfile Corp. – December 30, 2024) – Kuehn Law, PLLC, a shareholder litigation…